Pfizer reports top-line results from a Phase 3 study evaluating pregabalin controlled-release formulation as a treatment for patients with postherpetic neuralgia
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).